SIShingo Ishibashi

Shingo Ishibashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shingo Ishibashi has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Akihiko Tawara

    Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health

    1 shared publication
  • Naofumi Hirose

    Sakka Eye Clinic, Kitakyushu, Japan

    1 shared publication
  • Toshiaki Kubota

    Department of Ophthalmology, School of Medicine, University of Occupational and Environmental Health

    1 shared publication

Latest Publications

  • Effect of Latanoprost on the Diurnal Variations in the Intraocular and Ocular Perfusion Pressure in Normal Tension Glaucoma

    by Shingo Ishibashi, Naofumi Hirose, Akihiko Tawara, Toshiaki Kubota

    Purpose To evaluate the effects of latanoprost on the diurnal variations in the intraocular pressure (IOP) combined with the ocular perfusion pressure (OPP) in patients with normal tension glaucoma (NTG). Patients and Methods Twenty-two eyes from 22 patients with NTG were used for the study. The diurnal variations in the IOP and blood pressure (BP) were measured every 3 hours without therapy, and then the patients were treated with latanoprost (0.005%) once daily for more than 12 weeks. The diurnal variations in the IOP and BP under medication were again measured every 6 hours. The diurnal variation of IOP for 24 hours, mean diurnal IOP, maximum IOP, minimum IOP, range of variation in IOP, OPP, and BP were compared between the baseline and after treatment by means of a paired t test. Results At 3 months after the start of the latanoprost treatment regimen, the IOP showed a statistically significant decrease at every assessed time point over 24 hours (PPP>0.1), and BP (P>0.5) from the baseline. Conclusions Latanoprost was thus found to significantly reduce IOP over 24 hours, whereas it does not affect OPP and BP in NTG patients. Therefore, it may be a useful medication for NTG.